ADMA Biologics ADMA Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from ADMA Biologics’s reported figures.
Based on trailing twelve months.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's return on assets?
- ADMA Biologics (ADMA) reported return on assets of 28.1% in Q1 2026.
- How has ADMA Biologics's return on assets changed year-over-year?
- ADMA Biologics's return on assets decreased by 41.4% year-over-year, from 48% to 28.1%.
- What is the long-term trend for ADMA Biologics's return on assets?
- Over 5 years (2020 to 2025), ADMA Biologics's return on assets has grown at a -10.2% compound annual growth rate (CAGR), from -45.3% to 26.4%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.